Finnforel to Invest EUR 45 Million in New Production Facilities and Build First Selective Breeding Centre for Rainbow Trout in Finland
9.11.2021 12:25:00 EET | Business Wire | Press release
Finnish technology company Finnforel has become one of the world's leading ecological fish farms since it was founded in 2017. The company’s products are currently sold in more than a thousand grocery stores in Finland under the Saimaan Tuore brand. Finnforel achieved a significant breakthrough in November 2020, when its million-kilo production plant in Varkaus achieved maximum capacity level for premium fish farming.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211109005798/en/
Finnish technology company Finnforel has become one of the world's leading ecological fish farms since it was founded in 2017. With the investment programme announced today, Finnforel enters its next growth phase, as the company aims for rapid expansion in both the Finnish and global markets. (Photo: Business Wire)
With the investment programme announced today, Finnforel enters its next growth phase, as the company aims for rapid expansion in both the Finnish and global markets.
“Only 0.1 percent of all the fish in the world is produced in an ecologically sustainable way. This is a massive EUR 300 billion business that must change if we want to save our seas and lakes. I believe that Finnforel’s highly refined model, which works without antibiotics or environmental emissions, can claim a significant part of this market. Over the next decade, the mission of the Finnforel team is to bring Finnish genetics and fish farming know-how to the world. In the future, fish will be farmed where consumers are,” says Pekka Viljakainen, Chairman of the Board and one of the founders of Finnforel Oy.
Finnforel is further expanding the production capacity of its Varkaus plant from one million to three million kilos. The resulting “Finnforel Gigafactor” concept will cover the entire fish farming process, from juvenile fish to ready consumer products. Construction work on the extension, which will cost approximately EUR 25 million, will begin immediately. In December 2021, Finnforel will begin exporting its fish products to the United Kingdom, Germany and the Netherlands. At the same time, the company is entering the design phase for several similar gigafactor projects in Europe, Russia and the Middle East.
Finland’s first selective breeding centre for rainbow trout to be built in Hollola
A significant part of Finnforel’s expansion plans is to introduce to Finland industrial-scale broodstock and fry production suitable for Recirculating Aquaculture Systems. At present, most of the eggs used in fish farming in Finland are imported. Finnforel is building a EUR 12 million genetics and fry plant in Hollola that, upon completion, will have the capacity to produce eggs for six Finnforel gigafactor plants around the world.
The project, which is being implemented in close co-operation with Natural Resources Institute Finland, is also important in terms of Finland's emergency supply. Together with the Finnish institute, Finnforel will help secure the supply of fish eggs and fry, for example in crisis situations. Since the early 1990s, Natural Resources Institute Finland has carried out pioneering research in rainbow trout genetics, breeding and animal health. This project marks the first time that the results of this work are being applied and commercialised to this extent.
“According to the business model created by Finnforel, fish will be processed from eggs to consumer packaging. By securing the entire production chain, we create an easy way for consumers and retailers to buy and sell fresh and delicious fish. The consumption of fish is growing internationally, and I firmly believe that more vigilant consumers will increasingly favour organically produced alternatives that are easy and quick to prepare,” says Max Alfthan, Managing Director of Finnforel.
Significant new owners
Finnforel is financing these investments totalling EUR 45 million through a EUR 34 million share issue, EUR 4.5 million from the European Maritime and Fisheries Fund (EMFF) and EUR 6 million in loans from banks.
The share issue will make significant Finnish and international institutional investors shareholders in Finnforel. These include Ahlström Invest, Finnish Industry Investment Ltd (TESI), the European Investment Bank (European Fund for Strategic Investment), The Good Investors (Ireland/France) and other European family enterprises.
Finnforel’s press conference was held on Tuesday 9th of November from 11.00 am onwards. The recording of the press conference can be viewed here: https://www.finnforel.com/
Read more about Finnforel here: https://www.finnforel.com/
For more information: https://youtu.be/e6Q8LbLddXw
Finnforel Oy is a Recirculating Aquaculture Systems (RAS) facility and Finnish family business specialising in genetics and related technology that was founded in 2017. The company currently has pilot plants in Varkaus, Hollola and Joroinen that produce approximately one million kilos of organically farmed rainbow trout each year. The company's best-known brand is Saimaan Tuore, whose rainbow trout products are available in more than a thousand grocery stores throughout Finland.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211109005798/en/
Contact information
Further information:
Pekka Viljakainen, Chairman of the Board, Finnforel Oy
bulldozer@aii.fi, tel. +358 50 1422
Max Alfthan, Managing Director, Finnforel Oy
max.ahfthan@finnforel.com, tel. +358 40 0461640
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines Announces New Phase 3 Survival Data Reinforcing Benefit of ZIIHERA-Containing Regimens in First-Line HER2+ Gastroesophageal Cancer31.8.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive topline results from the second interim analysis (IA2) of the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA® (zanidatamab), in combination with chemotherapy, with and without TEVIMBRA® (tislelizumab), as first-line treatment for HER2+ locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). At IA2, ZIIHERA plus chemotherapy demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) compared with trastuzumab plus chemotherapy, meeting the remaining primary endpoint analysis of the study. IA2 also provided longer follow-up data for the TEVIMBRA plus ZIIHERA and chemotherapy regimen, demonstrating an improved OS hazard ratio, continued durable outcomes, and a generally manageable safety profile. These results reinforce findings from IA1, in which the regimen met the progression-free survival (PFS) and OS endpoints, wi
GigaDevice Strengthens EMEA and Southeast Asia Market Reach Through Strategic Partnership with Rutronik31.8.2026 10:00:00 EEST | Press release
GigaDevice, a leading semiconductor company specializing in Flash memory, 32-bit microcontrollers (MCUs), sensors, and analog products, today announced a new strategic franchise partnership with Rutronik Elektronische Bauelemente GmbH, one of Europe’s leading broadline distributors of electronic components. The agreement covers EMEA and Southeast Asia, including India, and provides customers with broader access to GigaDevice’s comprehensive portfolio of microcontrollers, sensors, and power management solutions. The partnership further strengthens GigaDevice’s distribution network and local market presence across key regions. With its strong presence across Europe and growing coverage in Southeast Asia, Rutronik provides GigaDevice with an established channel supported by extensive market reach, technical expertise, and customer relationships. The collaboration will help expand access to GigaDevice’s embedded solutions across a broad range of applications and industries, including indus
Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings30.8.2026 15:23:00 EEST | Press release
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the European Society of Cardiology (ESC) Congress 2026 demonstrating the strength of RNAi-powered silencing for cardiovascular disease. The findings further reinforce the clinical profile of AMVUTTRA® (vutrisiran) across transthyretin amyloidosis (ATTR) patient populations, treatment settings, and manifestations of disease. Additionally, the data expand the potential application of RNAi to uncontrolled hypertension, the world’s leading cause of cardiovascular disease. “With the power of our RNAi therapeutics platform, we have the potential to make a transformational impact on cardiovascular care,” said Pushkal Garg, M.D., Chief Research and Development Officer at Alnylam. “The data presented at ESC demonstrate the consistency of clinical outcomes achieved by RNAi-powered TTR silencing, reinforcing our conviction in AMVUTTRA as a first-line treatment option for ATTR-CM. With
New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202630.8.2026 00:54:00 EEST | Press release
Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon company, in strategic partnership with the Emirates Falconers’ Club, at ADNEC Centre Abu Dhabi. The exhibition runs until 6 September. The falcon, owned
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 01:40:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the total amount of blood in the body. Maintaining controlled hematocrit levels below 45% is the primary treatment goal in PV.1 “For patients living with PV, uncontrolled hematocrit can have serious consequences, including an elevated risk of life-threatening thrombotic events," said Andrew T. Kuykendall, M.D., VERIFY lead investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “Curre
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
